B. Riley Securities maintains Neuronetics at Buy, raises price target to $6 from $5
B. Riley Securities reaffirmed its Buy rating for Neuronetics and increased its price target to $6 from $5, suggesting a 146.9% upside from the Nov 5 close of $2.43, according to the firm.
How this was made

The 30-second read
Why it matters
The price‑target increase suggests a short‑term upside opportunity.
Market read
Analyst target raise provides a fresh catalyst for a micro‑cap stock.
What to watch
Potential regulatory delays or competitive pressures not addressed in the note.
Background
Neuronetics (STIM) is a small‑cap neurotechnology company; analyst coverage is sparse.
Ticker impact
B. Riley raised Neuronetics' price target to $6, indicating a bullish analyst view.
potential upward pressure as investors price in the higher target
Target increase signals improved outlook, likely prompting short-term buying.
Market effects
May lift sentiment in the neurotechnology/medical device sector.
Limited to US small‑cap investors.
Low, confined to Neuronetics and its niche peers.
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- analystB. Riley Securities
Equity research firm issuing the rating upgrade.

